RCM
SNTI icon

Radcliffe Capital Management’s Senti Biosciences Holdings SNTI Stock Holding History

Radcliffe Capital Management’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,089
Closed -$206K – 1249
2022
Q1 		$206K Hold
2,089
– – ﹤0.01% 1178
2021
Q4 		$206K Hold
2,089
– – 0.01% 1025
2021
Q3 		$208K Buy
+2,089
New +$206K 0.01% 871

Other funds holding SNTI

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
IC
Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
KC
Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

Radcliffe Capital Management's SNTI Position: Q2 2022 in Review

Radcliffe Capital Management sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 2,089 shares — an estimated $206K sold.

Radcliffe Capital Management first reported a position in SNTI in Q3 2021 and held it in 3 quarters. The position peaked at $208K in Q3 2021. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

  • Radcliffe Capital Management reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
  • Radcliffe Capital Management sold 2,089 Senti Biosciences Holdings shares in Q2 2022, an estimated $206K.
  • Radcliffe Capital Management first reported a position in Senti Biosciences Holdings in Q3 2021 and held it in 3 quarters.
  • Radcliffe Capital Management's Senti Biosciences Holdings position peaked at $208K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on Radcliffe Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.